Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML

New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form of acute myeloid leukemia (AML).

  • By

  • August 26, 2026

  • 3 min

Share

Original Source(s)

Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML

  • by

  • August 26, 2026

Related Content

Author Correction: Low-protein diet enhances antitumor immunity in pancreatic cancer through microbiota-derived UDP-galactose

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

Commentary: Baseline systemic immune-inflammation index and a novel FLIPI-SII model predict POD24 and long-term survival in grade 1–3a follicular lymphoma